Abstract Session 3: Novel combinations, access and long term outcomes

Co-Chair(s)

• 

  Gordon Cook, PhD

  Clinical Professor
  Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
  Leeds, United Kingdom
• 

  Eirini Katodritou, MD, PhD (she/her/hers)

  Hematology Consultant
  Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece
  Thessaloniki, Thessaloniki, Greece

Presentations:

• 5:15 PM – 5:27 PM EEST

  OA-41: Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial
  

  Speaker: Darrell White, MD (he/him/his) – Dalhousie University and Queen Elizabeth II Health Sciences Centre
• 5:27 PM – 5:39 PM EEST

  OA-29: First Results From the Randomized Portion of a Phase 2 Study of Venetoclax Plus Carfilzomib-Dexamethasone vs Carfilzomib-Dexamethasone in Patients With t(11;14) Relapsed/Refractory Multiple Myeloma
  

  Speaker: Jonathan L. Kaufman, MD – Winship Cancer Institute of Emory University
• 5:39 PM – 5:51 PM EEST

  OA-44: Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial
  

  Speaker: Meral Beksac, MD (she/her/hers) – Ankara University
• 5:51 PM – 6:03 PM EEST

  OA-42: Second Primary Malignancies after Tandem Autologous Hematopoietic Stem Cell Transplantation for patients with Multiple Myeloma Treated on Earlier Total Therapy Protocols
  

  Speaker: Samer Al Hadidi, MD,MS,FACP – the University of Arkansas for Medical Sciences
• 6:03 PM – 6:15 PM EEST

  OA-54: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma patients: final results of the phase 2 study IFM 2018-04
  

  Speaker: Cyrille Touzeau, MD, PhD – CHU Nantes